Australia markets closed

MGC Pharmaceuticals Limited (MXC.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.4100-0.0100 (-2.38%)
At close: 03:38PM AEDT
Full screen
Previous close0.4200
Open0.4200
Bid0.4100 x 125665700
Ask0.4200 x 8008500
Day's range0.4100 - 0.4200
52-week range0.3000 - 13.0000
Volume25,533
Avg. volume14,606
Market cap17.979M
Beta (5Y monthly)1.00
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • PR Newswire

    MGC Pharma Rebrands as Argent BioPharma in Strategic Transformation

    MGC Pharmaceuticals Ltd (LSE: MXC), (OTC: MGCLF), (ASX: MXC) Rebrands as Argent BioPharma in Strategic TransformationMarking a significant milestone in its evolutionary journey, MGC Pharma has officially announced its rebranding to Argent BioPharma, pending approval from its shareholders. This rebranding is the culmination of an extensive restructuring, incorporating significant American capital and operational revisions. Poised for growth, Argent BioPharma is now set to emerge as a key player i

  • PR Newswire

    Historic Milestone: UK Patients Receive First CannEpil® Delivery through 'I AM Billy Foundation' and GMC Specialist Register

    MGC Pharmaceuticals Ltd. (LSE: MXC), (ASX: MXC), (OTC: MGCLF), a leading European pharmaceutical firm specializing in plant-derived medications, announced today that its ground-breaking Investigational Medicinal Product (IMP), CannEpil®, has been successfully imported and received by its first patients in the United Kingdom.

  • PR Newswire

    MGC Pharma's CannEpil® Now Accessible to UK Patients on Named Patient Request Basis

    MGC Pharmaceuticals Ltd. (LSE: MXC), (ASX: MXC), (OTC: MGCLF), a European based pharmaceutical company specializing in the development and supply of affordable, ethically produced plant-inspired medicines, announces that its proprietary product CannEpil® is now available to patients in the UK by Named Patient Request.